These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7051538)

  • 21. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J; Ye P
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].
    Vaverková H; Novotný D; Ficker L
    Vnitr Lek; 1996 Apr; 42(4):239-45. PubMed ID: 8693709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering effects of procetofene.
    Afschrift M; Mets T; Verdonk G
    Lancet; 1977 Aug; 2(8032):311. PubMed ID: 69930
    [No Abstract]   [Full Text] [Related]  

  • 24. [The apoB genotype and the efficacy of hypolipidemic therapy].
    Tseluĭko VI; Kravchenko NA; Chernyshov Va; Maksimova NA; Nazarenko IL
    Tsitol Genet; 1998; 32(1):126-34. PubMed ID: 9695263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].
    Fromantin M; Gautier D; Quatre JM; Bon R
    Therapie; 1981; 36(4):473-6. PubMed ID: 7292431
    [No Abstract]   [Full Text] [Related]  

  • 26. Ezetimibe coadministered with fenofibrate: some safety questions.
    Borja J
    Eur Heart J; 2005 Nov; 26(21):2344; author reply 2344. PubMed ID: 16123048
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients.
    Weiss P; Dujovne CA; Margolis S; Lasagna L; Bianchine JR
    Clin Pharmacol Ther; 1970; 11(1):90-6. PubMed ID: 4903694
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical and biological aspects of hyperlipemia].
    Turcanu V; Bartl F; Fiat F
    Med Interna (Bucur); 1970 Apr; 22(4):489-93. PubMed ID: 4246119
    [No Abstract]   [Full Text] [Related]  

  • 29. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
    Zvenigorodskaia LA; Mel'nikova NV; Bondarenko EIu
    Eksp Klin Gastroenterol; 2007; (1):41-6. PubMed ID: 17547112
    [No Abstract]   [Full Text] [Related]  

  • 31. [Study of hepatic tolerance after 4 years of treatment with procetofene].
    Fromantin M; Drouin P; Sauvanet JP; Rouffy J
    Nouv Presse Med; 1978 Mar; 7(11):938. PubMed ID: 643562
    [No Abstract]   [Full Text] [Related]  

  • 32. Statins and fibrates in the management of diabetic dyslipidemia.
    Durrington P
    Diabet Med; 1997 Jul; 14(7):513-6. PubMed ID: 9223386
    [No Abstract]   [Full Text] [Related]  

  • 33. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics of fenofibrate in man (author's transl)].
    Harvengt C; Desager JP
    Nouv Presse Med; 1980 Dec; 9(49):3725-7. PubMed ID: 7208337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of fenofibrate.
    Telford M
    Curr Med Res Opin; 2003; 19(2):139; author reply 139-40. PubMed ID: 12740159
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
    Landry P; Dimitri E; Tessier S; Légaré N
    J Clin Psychopharmacol; 2008 Jun; 28(3):348-9. PubMed ID: 18480696
    [No Abstract]   [Full Text] [Related]  

  • 37. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
    Ivanova TN; Poliakova ED; Olfer'ev AM; Perova NV
    Biull Eksp Biol Med; 1998 May; 125(5):569-73. PubMed ID: 9644562
    [No Abstract]   [Full Text] [Related]  

  • 40. Rare side-effects of fenofibrate.
    Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L
    Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.